Previous research has demonstrated that Sycn was a potential pancreatic tumor biomarker for the early detection of pancreatic secretions in pancreatic cancer patients by quantitative proteomic analysis [35], [37]. The gene discussed is SYCN; the disease is pancreatic neoplasm.